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Manuscript
Abstract 
The importance of the innate immune system, including complement, in causing transplant 
injury and augmenting adaptive immune responses is increasingly recognised. Therefore 
variability in graft outcome may in part be due to genetic polymorphism in genes encoding 
proteins of the immune system. This study assessed the relationship between single 
nucleotide polymorphisms (SNPs) in complement genes and outcome after transplantation. 
Analysis was performed on two patient cohorts of 650 and 520 transplant recipients. 505 
tagged SNPs in 47 genes were typed in both donor and recipient. The relationships between 
SNPs and graft survival, serum creatinine, delayed graft function and acute rejection were 
analysed. One recipient SNP in the gene encoding mannose binding lectin was associated 
with graft outcome after correction for analysis of multiple SNPs (p=6.41 x 10-5). When 
further correction was applied to account for analysis of the effect of SNPs in both donor and 
recipient this lost significance. Despite association p values of <0.001 no SNP was 
significantly associated with clinical phenotypes after Bonferroni correction. In conclusion, 
the variability seen in transplant outcome in this patient cohort cannot be explained by 
variation in complement genes. If causal genetic effects exist in these genes, they are too 
small to be detected by this study. 
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Introduction 
The complement system is a major element of the innate immune system. Its main 
physiological function is the killing and elimination of pathogens, apoptotic cell debris and 
immune complexes. It achieves this by formation of the pore forming membrane attack 
complex C5b-9, release of the potent inflammatory mediators C3a and C5a and by 
opsonisation, primarily with C3b. Complement is activated by three pathways that converge 
with the assembly of C3 and C5 convertases and subsequent amplification of the cascade. 
Excessive or inappropriate activation of complement can lead to tissue injury, so to prevent 
damage a series of serum and membrane bound inhibitors exist to limit activation directed at 
self. Despite these inhibitors, complement-mediated tissue injury is well documented. 
In transplantation complement activation can occur at many stages and there is increasing 
evidence that it contributes to graft damage. Reperfusion of an ischemic graft leads to 
complement activation (Zhou, et al., 2000) and complement inhibition reduces injury (Pratt, 
et al., 2003, Thurman, et al., 2006). The presence of preformed or new donor specific 
antibodies leads to complement activation via the classical pathway. Hyperacute rejection is 
now rarely seen but acute and chronic antibody mediated rejection is increasingly 
recognised and complement is both a biomarker and probable mediator of graft injury 
(Stegall and Gloor). 
The capacity of the transplanted graft to synthesise many complement proteins adds further 
complexity to complement’s role in transplant injury. Complement gene expression is up-
regulated by donor factors prior to transplantation and higher pre-transplant expression is 
associated with both early and late graft dysfunction (Naesens, et al., 2009, Hauser, et al., 
2004). It is evident from studies in mice that the intra-renal synthesis of C3, the pivotal 
complement protein, contributes both ischemia reperfusion injury (Farrar, et al., 2006) and 
acute rejection (Pratt, et al., 2002). In patients, local expression of C3 in the transplanted 
kidney increases during acute rejection (Andrews, et al., 1994), spilling over into the 
circulation where it can contribute 10% of total C3 (Tang, et al., 1999).  
There are a number of potential ways in which complement activation can contribute to graft 
rejection. Complement proteins can directly damage renal cells, a mechanism likely to 
contribute to acute antibody-mediated rejection. Sublytic deposition of membrane attack 
complex on cells can induce synthesis of cytokines and growth factors which, with the 
anaphylotoxins, can enhance graft inflammation and fibrosis. As well as its well documented 
influence on B cell immunity (Dempsey, et al., 1996), complement can also augment the T-
cell allo-immune response (Heeger, et al., 2005). Complement receptor binding of opsonised 
cells increases interaction between lymphocytes and antigen presenting cells (APC) 
(Kerekes, et al., 1998) and C3a and C5a can activate and drive T cells into specific effector 
phenotypes (Lalli, et al., 2007, Liu, et al., 2008, Peng, et al., 2008, Peng, et al., 2009). 
Complement-mediated inflammatory injury may also provide a source of antigen and alter 
the local inflammatory environment (Lewis, et al., 2008). Whatever the mechanism, it is clear 
from animal studies that blocking complement effector functions can dramatically improve 
graft survival (Gueler, et al., 2008, Rother, et al., 2008, Pavlov, et al., 2008). 
There is significant variation in transplantation outcome. Differences in outcome can in part 
be explained by factors such as donor age and ischemic time. However, this is insufficient to 
explain all the variation seen and the possible influence of both donor and recipient genetic 
risk factors has been proposed. The known contribution of genetic variation in major 
histocompatibility antigens does not fully explain differences in outcome (Su, et al., 2004).   
As with many genes, those of the complement system contain many polymorphisms with 
putative functionality. The C3 gene has many polymorphic variants, the best known being 
the F/S polymorphism (rs2230199). The F/S polymorphism has been associated with many 
inflammatory diseases and we reported an effect on transplant outcome (Brown, et al., 
2006), although this was not replicated in a subsequent study (Varagunam, et al., 2009). 
Other studies have reported an effect of complement polymorphism following 
transplantation. For example polymorphisms in Mannose-binding lectin (MBL) have been 
implicated in the development of ischemic renal injury (de Vries, et al., 2004). The serum 
concentration of MBL is determined by promoter and exon 1 polymorphisms and these 
SNPs influence graft survival after kidney (Berger, et al., 2005), simultaneous pancreas-
kidney (Berger, et al., 2007), lung transplantation (Munster, et al., 2008) and have been 
associated with risk of infections post-transplantation (Verschuren, et al., 2008, Cervera, et 
al., 2009). 
Genetic variation in the complement pathway could explain some of the variability in 
transplant outcome. In this study we have used a set of tagged single nucleotide 
polymorphisms (SNPs) across all complement genes to determine the effects of genetic 
polymorphic variation in complement genes on renal transplant outcome.  
 
Materials and methods 
Sample collection 
The sample and data collection and analysis was approved by the local Research Ethics 
Committee (24932).  Donor and recipient pairs were identified for which DNA was available 
from both parties. DNA was identified in donor and recipient pairs transplanted at Guy’s and 
St Thomas’ Hospital NHS Foundation Trust between 1993 and 2004 (KCL cohort, 650 pairs) 
and at Newcastle upon Tyne Hospitals NHS Foundation Trust between 1994 and 2005 (NCL 
cohort, 520 pairs). Only donor-recipient pairs who were aged over 18 years at the time of 
transplantation were included. To reduce the possibility of confounding due to population 
stratification, only Caucasian donors and recipients were included in the study. 
 
Definition of phenotypes 
Graft survival was defined as days from transplant date to a graft failure event: defined as a 
return to dialysis; a return to the transplant waiting list; or re-transplantation.   Patients were 
defined as having acute rejection if they had one or more episodes of acute rejection that 
was biopsy proven (Banff (97) categories 2 and 4 (KCL patients only)).  Delayed graft 
function was defined as the need for dialysis within the first week post-transplantation. 
Serum creatinine (Cr) measurements were supplied by the renal unit responsible for patient 
follow up. The serum Cr concentration at 1, 3 and 5 years (mean of the 3 measures closest 
to each time point) after kidney transplant was used for analysis. Grafts that had failed (as 
defined above) were not included in the analysis. 
 
SNP selection and genotyping 
SNPs were selected to cover 47 genes considered by expert review to be the principal 
genes involved in the complement pathway (Supplementary Table 1 and 2).  For tagging 
purposes, genes were clustered together into groups whenever inter-gene distances were 
less than 200kb.  A hybrid tagging-plus-putative-function selection strategy was used, similar 
in design to Cavalleri et al. (Cavalleri, et al., 2007). First, common SNPs with putative 
functional effect were selected using the TAMAL v2 program (Hemminger, et al., 2006).  
SNPs were selected if there was evidence that the minor allele frequency (MAF) was greater 
than 5% in European populations and one of the following functional criteria were met: (1) 
non-synonymous coding SNP; (2) SNP within predicted promoter region; (3) SNP within 
evolutionarily conserved region; (4) SNP within predicted transcription factor binding site; (5) 
SNP within conserved miRNA target; or (6) SNP within a splice region.  Some additional 
putative functional SNPs were also added via a manual literature search.  106 putative 
functional SNPs were selected in this way.  Next, these SNPs were assessed for their 
linkage disequilibrium tagging ability using the Tagger program (de Bakker, et al., 2005), and 
additional SNPs were chosen to ensure an r2 greater than 0.9 with all SNPs with MAF>5% in 
the HapMap Phase 2 European-ancestry sample and residing within the transcribed region 
of each gene.  This resulted in 505 SNPs being selected for genotyping (Supplementary 
Table 2). 
 
This set of SNPs was typed in our DNA samples by Sequenom using the iPlex platform. This 
utilises a multiplex PCR system followed by a single base pair extension step to produce 
primer extension products which are then analysed by MALDI-TOF mass spectrometry. 
 
SNPs and DNA samples were subjected to the following quality control procedures. Sample 
were excluded if they could not be matched to the clinical database; if they had a reported 
gender in the clinical database incompatible with observed X-chromosome genotypes; if they 
had genotypes which completely matched another sample (with the exception of one known 
monozygotic twin pair); or if they had more than 20% missing genotype data in either the 
KCL or Newcastle datasets.  SNPs were excluded if they had more than 10% missing data; 
if they had a sample MAF<0.002, or if they had an exact-test p-value for departure from 
Hardy-Weinberg equilibrium <0.001.  QC resulted in final post-QC figures of 1295 samples, 
621 donor-recipient pairs and 416 SNPs in the KCL dataset, and 1039 samples, 512 donor-
recipient pairs and 448 SNPs in the Newcastle dataset. 409 SNPs passed QC in both 
datasets. 
 
Selection of covariates 
A model selection procedure on the clinical variables available to us was performed to 
identify which covariates should be entered into downstream analysis.  We carried out a 
stepwise Cox proportional hazards model selection procedure on graft survival in the KCL 
cohort, using the AIC-based forward-backward model selection procedure implemented in 
the step() function of the R statistical package (http://www.r-project.org/), based on the 
following variables: date of transplant, follow-up unit code, donor and recipient gender, donor 
and recipient age, donor cause of death, number of previous grafts received by the recipient, 
graft origin (local / imported), donor type (cadaveric / living), transplant state (heartbeating / 
non-heartbeating), donor-recipient relatedness (e.g. 0 for unrelated, 0.5 for full sibs), and 
broad specificity mis-match status entered separately for HLA-A, -B and –DRB.  The three 
variables emerging with the strongest statistical support for an effect on graft survival were 
donor type (cadaveric / living), recipient age and donor age.  However, because of missing 
data values for donor age only donor type and recipient age were used as covariates in all 
downstream analyses.  For comparison we also ran our graft survival analyses on the KCL 
dataset using the top 6 covariates (donor type, recipient age, donor age, HLA-DRB 
mismatch, number of previous grafts, and recipient gender), and failed to find any significant 
hits for this analysis (data not shown). 
 
Association analysis 
Graft survival was tested via Cox proportional hazards modelling.  Binary endpoints (acute 
rejection, delayed graft function, data from KCL cohort only) were tested via logistic 
regression.  Creatinine levels after one, three and five years, as well as the difference 
between one and three and one and five years, were tested via standard linear regression.  
All association analyses employed the same covariates as previously described. 
Graft survival analyses were performed on the combined KCL and Newcastle datasets, with 
centre origin (KCL / Newcastle) added as an additional covariate.  Within cohort analyses 
were performed to establish whether association effects were consistent in direction 
between the two centres.  Creatinine analyses were performed separately on KCL and 
Newcastle datasets, because creatinine measurements were undertaken using separate 
protocols at the two centres. 
Unless otherwise stated, all analyses tested a linear effect of allele ‘dose’ on the phenotype 
when transformed on the relevant scale, with minor homozygotes / heterozygotes / major 
homozygotes coded as 0/1/2 respectively.  Three genetic association effects were tested for 
each SNP on each phenotype: a donor genotype main effect, a recipient genotype main 
effect, and a donor x recipient linear interaction effect. Tests were performed using likelihood 
ratio tests that compared the model with the effect against the relevant simpler hierarchical 
model (interaction effects were tested with main effects present in both models). All 
statistical analyses were done with Plink software version 1.07 (http://pngu.mgh.harvard.edu/ 
∼ purcell/plink/) and the R statistical package version 2.14 (http://www.r-project.org/).   
 
Results 
Transplant survival 
Donor, recipient and interaction associations were assessed between SNPs in the 
complement system and transplant survival, censoring for death with a functioning graft (with 
transplant type and recipient age as covariates). The SNPs that had low p values in both the 
KCL and NCL cohorts are presented in Table 1. The SNP most closely associated with graft 
loss was in the gene encoding mannose binding lectin (rs4935047, donor main effect, 
p=6.41x10-5) (Figure 1). This is a significant association when the Bonferroni correction is 
applied to correct for analysis of multiple SNPs (alpha=1.2 x 10-4). However, each SNP was 
tested for donor, recipient and interaction effects. When a further correction is made to 
account for this, formal significance is lost (alpha=4.1 x 10-5). There are 4 SNPs in 
complement C7 with P<0.01. The presence of 4 SNPs in this list may be explained by 
linkage disequilibrium between the SNPs. 
Additional survival analyses were performed treating death with a functioning graft as a 
failure event. The ten SNPs with the lowest p values and consistent in-group effect are 
shown in Table 2. No SNP demonstrated a significant association with graft survival after 
correction for multiple tests but again there are SNPs with low P values in genes within the 
lectin pathway and C7. Although this raises the possibility of a biological effect, further 
studies would be needed to determine whether an effect was present. No effect of the SNP 
(rs2230199) responsible for the F/S polymorphism in C3 was observed. 
 
Serum Creatinine 
Serum Cr was used as a biomarker to assess whether complement SNPs were associated 
with graft function. Associations with Cr at 1, 3 and 5 years following transplantation as well 
as the change in Cr between these time points were assessed. The ten SNPs with the 
lowest p value are shown in Table 3 for the KCL (A) and NCL (B) cohorts. The lowest p 
value achieved in either cohort was for a SNP in MBL (rs930507, recipient main effect in 
delta-Cr between 1 and 3 years post-transplant, p=7.16 x 10-5) (Figure 2). However, this did 
not reach statistical significance after correction for multiple analyses (alpha=2.26 x 10-5) and 
this was not replicated in the NCL cohort. 
 
Delayed graft function and acute rejection 
Associations between complement SNPs and two other transplant phenotypes, delayed graft 
function and biopsy proven acute rejection were also tested. Biopsy analysis was derived 
from clinical reports using the same Banff criteria. SNPs with the lowest p values are shown 
for these two phenotypes are shown in Tables 4A and 4B. Although SNPs were associated 
with both of these phenotypes with a significance level of p<0.001, this association was not 
significant after Bonferroni correction for multiple tests (alpha=1.11 x 10-4) 
 
 
Discussion 
This study represents the largest and most comprehensive study on the effect of 
complement genetics of both short-term and long-term renal transplant outcomes. Donor 
and recipient genotypes were tested along with their putative interaction effects.  Despite 
possessing larger sample sizes than previous studies, we failed to find any significant effects 
after correcting for the multiple tests implicit in our study design.  
The complement system has been implicated in the pathogenesis of renal allograft injury at 
several stages during the life of the graft. Even prior to implantation complement gene 
expression is increased in grafts and the magnitude of this increase correlates with long-
term graft outcome (Naesens, et al., 2009). Complement is activated in a kidney at the time 
of reperfusion and there are many pre-clinical studies showing that preventing complement 
activation has a beneficial effect (Lewis, et al., 2008, Pratt, et al., 1996). Complement 
activation influences the development allo-immune responses in experimental models of 
kidney transplantation, altering T cell and dendritic cell function (Pratt, et al., 1997). 
Inflammatory damage to the graft caused by complement activation may provide a source of 
alloantigen and a stimulus to the adaptive immune response. (Peng, et al., 2008).  
In addition to the known effects of complement in transplantation there are reports of 
polymorphic variation in complement genes affecting the outcome after kidney 
transplantation (Brown, et al., 2006, Gunesacar, et al., 2015, Jeong, et al., 2011).  However, 
an independent study did not find an association with C3 polymorphisms and transplant 
outcome (Varagunam, et al., 2009), and although a more recent study has shown that donor 
C3F allotype protects from primary non-function there was no effect on long-term outcome 
(Damman, et al., 2012). These findings suggest that the original finding was a false positive.  
Graft survival is a complex phenotype affected by many donor and recipient factors. Part of 
the variability in kidney transplant outcome is explained by polymorphic variation in the Major 
Histocompatibilty Complex (MHC) and other loci possibly associated with immune function 
(O'Brien, et al., 2013). Given this, and given the general observation that any complex trait, 
when examined in sufficient depth, yields multiple controlling genetic loci, and given that a 
role for the complement system in transplantation is becoming increasing more likely from 
molecular studies, we propose that the negative findings from our study are more likely to 
stem from a lack of power to detect genetic signals in the genes examined than from a 
complete absence of such signals.  The lack of power can be attributed to any one, or a 
combination, of the following factors: (1) low effect sizes, implying insufficient sample sizes; 
(2) low linkage disequilibrium between causal variants and the SNPs typed in our study; (3) 
(for the survival and quantitative trait analyses) insufficient control for other major covariates, 
such that genetic signals are swamped by noise. 
We acknowledge that all three of the above may have played a part in our negative findings.  
With regards to linkage disequilibrium, we note that at the time of the design of our SNP 
panel, the HapMap Phase II dataset was the best resource available for determining linkage 
disequilibrium among common SNPs.  Since then, more extensive datasets such as the 
1000 genomes resource have become available, and it has been noted, for example, that 
some common polymorphisms of potential functional significance in MBL2 are not well 
tagged by our panel because they were not present in the HapMap Phase II dataset.  
Furthermore, the fact that 12% of our SNPs failed QC due to technical issues (standard for 
custom-designed panels of this nature) means that gaps in the coverage for some genes 
exist. 
With regards to the effect of covariates on survival and quantitative trait analyses (note 
binary trait analyses should not be affected because these covariates are likely to be 
uncorrelated with our genetic traits), we carried out a model selection process to include any 
covariates present in our clinical database that had a demonstrably large effect on graft 
survival in our cohorts.  We accept, however, that our clinical database did not include a 
number of variables of potential relevance, including underlying renal disease, cold ischemic 
time, donor baseline pathology, HLA immunization, drug regimen and compliance.  Missing 
data presented a consequent problem for downstream analysis.  
Candidate gene association studies, even those that have examined many genes across a 
single pathway, have had a mixed record in identifying genetic variants for complex traits 
(Ioannidis, 2005, Lohmueller, et al., 2003).  However, the well-known effects at the HLA 
locus, and the fact that renal transplants between identical twins have the best graft survival 
outcomes, are proof that genetic effects are certainly at work in renal transplant outcomes.  
Elucidation of these await the implementation of still larger studies.   
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Table legends 
Table 1. SNPs with lowest p-values for association with graft survival (combined analysis 
across both KCL and NCL cohorts) and consistent within-cohort effects. Patient death was 
treated as a censoring event.  SNPs are ordered by overall p-value regardless of the genetic 
effect tested.  SNP – rs Identifier (effect; S – synonymous, NS – non-synonymous, NC – 
non-coding); Gene - nearest gene; MAF - minor allele frequency; Log hazard ratio (all) - 
natural log of hazard ratio for heterozygotes versus major homozygote (all data); Log hazard 
ratio (KCL) - natural log of hazard ratio for KCL data only; Log hazard ratio (NCL) - natural 
log of hazard ratio for NCL data only; SE (all) / p-value (all) / N (all) = standard error/p-
value/non-missing-data-size for log hazard ratio (all); Effect = D if donor main effect, R if 
recipient main effect, I if DxR interaction. Bonferroni corrected alpha level = 4.1E-05. 
 
Table 2. SNPs with lowest p-values for association with graft survival (combined analysis 
across both KCL and NCL cohorts) and consistent within-cohort effects.. Patient death 
treated as a failure event failure.  SNPs are ordered by overall p-value regardless of the 
genetic effect tested.  SNP – rs Identifier (effect; S – synonymous, NS – non-synonymous, 
NC – non-coding); Gene - nearest gene; MAF - minor allele frequency; Log hazard ratio (all) 
- natural log of hazard ratio for heterozygotes versus major homozygote (all data); Log 
hazard ratio (KCL) - natural log of hazard ratio for KCL data only; Log hazard ratio (NCL) - 
natural log of hazard ratio for NCL data only; SE (all) / p-value (all) / N (all) = standard 
error/p-value/non-missing-data-size for log hazard ratio (all); Effect = D if donor main effect, 
R if recipient main effect, I if DxR interaction. Bonferroni corrected alpha level = 2.26E-05. 
 
 
Table 3. SNP associations with serum creatinine.  The top ten SNPs associated with serum 
creatinine in the KCL patient cohort (A) and the NCL patient cohort (B). SNP – rs Identifier 
(effect; S – synonymous, NS – non-synonymous, NC – non-coding); Gene - nearest gene; 
MAF - minor allele frequency; SE/p-value/N - standard error/p-value/non-missing-data-size 
for Slope; CRT1Y - Creatinine at 1 year; CRT3Y - Creatinine at 3 years; CRT5Y - Creatinine 
at 5 years; CRT1_3Y - Change in creatinine between 1 and 3 years; CRT1_5Y - change in 
creatinine between 1 and 5 years; Effect - D if donor main effect, R if recipient main effect, I 
if DxR interaction. Bonferroni corrected alpha level = 2.26E-05. 
 
Table 4. SNP associations for acute rejection and delayed graft function.  The top ten SNPs 
associated with biopsy proven acute rejection in the KCL patient cohort (A). The top ten 
SNPs associated with biopsy proven acute rejection in the KCL patient cohort (B). SNP – rs 
Identifier (effect; S – synonymous, NS – non-synonymous, NC – non-coding, MIS - 
Missense); Gene - nearest gene; MAF - minor allele frequency; SE/p-value/N - standard 
error/p-value/non-missing-data-size for Slope; OR – Odds ratio. Effect - D if donor main 
effect, R if recipient main effect, I if DxR interaction. Bonferroni corrected alpha level = 
1.113E-04. 
 
Table 1 
 
 
SNP (effect) Gene MAF Log hazard 
ratio (all) 
Log hazard 
ratio (KCL) 
Log hazard 
ratio (NCL) 
SE 
(all) 
p-value 
(all) 
N 
(all) 
Effect 
rs4935047 (NC) MBL2 0.441 -0.402 -0.410 -0.393 0.169 6.41E-05 1120 D 
rs874603 (NC) MASP1 0.076 -1.882 -3.260 -0.849 1.001 2.72E-04 1115 R 
rs1910016 (NC) C7 0.488 -0.383 -0.101 -0.772 0.204 1.18E-03 1041 D 
rs12658133 (NC) C7 0.189 0.690 0.610 0.771 0.228 1.89E-03 1098 I 
rs419137 (NC) CFH 0.125 0.877 0.968 0.566 0.629 2.69E-03 1096 R 
rs3792640 (NC) C7 0.192 0.607 0.542 0.665 0.222 5.24E-03 1115 I 
rs2455308 (NC) C7 0.192 0.643 0.631 1.322 0.238 5.44E-03 1126 I 
rs2842704 (NC) C4BPA 0.141 -0.832 -0.968 -0.837 0.289 5.50E-03 1091 I 
rs1048971 (S) CR2 0.360 0.086 0.062 0.191 0.206 5.54E-03 1107 R 
rs7499077 (NC) ITGAM 0.278 0.500 0.466 0.581 0.188 6.90E-03 1096 I 
 
 
 
Table 2 
 
 
SNP (effect) Gene MAF Log hazard 
ratio (all) 
Log hazard 
ratio (KCL) 
Log hazard 
ratio (NCL) 
SE 
(all) 
p-value 
(all) 
N 
(all) 
Effect 
rs1078375 (NC) C7 0.417 -0.442 -0.337 -0.534 0.119 2.16E-04 1047 I 
rs4935047 (NC) MBL2 0.441 -0.236 -0.233 -0.233 0.139 3.28E-04 1120 D 
rs294185 (NC) C1QG 0.390 0.383 0.237 0.575 0.119 1.21E-03 1108 I 
rs4151657 (NC) BF 0.331 0.397 0.561 0.104 0.134 2.83E-03 1115 I 
rs2675982 (NC) C7 0.069 -0.627 -0.613 -0.376 0.683 4.25E-03 1124 R 
rs6772329 (NC) MASP1 0.081 -1.870 -2.873 -1.393 0.832 4.32E-03 1059 D 
rs2443040 (NC) C7 0.375 0.373 0.365 0.404 0.132 4.57E-03 1033 I 
rs7545126 (NC) MCP 0.110 -0.646 -0.202 -1.168 0.594 5.81E-03 1109 R 
rs6772329 (NC) MASP1 0.081 1.045 1.450 0.878 0.438 6.96E-03 1059 I 
rs1143664 (S) C1S 0.075 -0.999 -1.142 -0.108 0.368 8.08E-03 1118 I 
 
Table 3 
A 
 
SNP (effect) CHR Gene MAF Coefficient SE p-value N Effect Creatinine 
rs930507 (S) 10 MBL2 0.161 -15.989 3.972 7.16E-05 317 R CRT1_3Y 
rs6602392 (NC) 10 IL2RA 0.107 -16.017 4.334 2.53E-04 376 D CRT1Y 
rs11569450 (NC) 19 C3 0.105 18.765 5.350 5.31E-04 269 R CRT1_5Y 
rs2300955 (NC) 1 C8A 0.182 -12.948 3.724 5.67E-04 380 D CRT1Y 
rs5964488 (NC) 23 VSIG4 0.155 -11.102 3.224 6.40E-04 372 D CRT1Y 
rs835209 (NC) 5 C9 0.035 -26.550 7.764 7.00E-04 362 D CRT1Y 
rs11569523 (NC) 19 C3 0.056 21.800 6.437 8.17E-04 268 R CRT1_5Y 
rs2300955 (NC) 1 C8A 0.182 -32.434 9.868 1.11E-03 385 I CRT3Y 
rs11569523 (NC) 19 C3 0.056 18.952 5.794 1.19E-03 328 R CRT1_3Y 
rs619545 (NC) 1 C8A 0.267 10.173 3.158 1.39E-03 374 D CRT1Y 
 
 
         
B 
 
 
SNP (effect) CHR Gene MAF Coefficient SE p-value N Effect Creatinine 
rs7519492 (NC) 1 intergenic 0.130 -8.612 21.027 1.28E-04 361 R CRT3Y 
rs16840422 (NC) 1 CFH 0.140 -40.170 15.342 1.71E-04 337 R CRT1_3Y 
rs7519492 (NC) 1 intergenic 0.130 -36.495 14.713 1.80E-04 341 R CRT1_3Y 
rs1738548 (NC) 11 CD59 0.278 18.767 17.722 1.98E-04 184 I CRT5Y 
rs16840422 (NC) 1 CFH 0.140 -13.132 21.896 2.74E-04 357 R CRT3Y 
rs1887632 (NC) 1 CR1 0.091 -34.981 14.773 3.06E-04 333 I CRT1_3Y 
rs6674522 (NC) 1 CFHR2 0.112 -37.659 15.288 5.65E-04 335 R CRT1_3Y 
rs710459 (NC) 3 MASP1 0.427 -1.832 11.911 6.05E-04 188 D CRT1_5Y 
rs11569450 (NC) 19 C3 0.111 -11.408 21.787 6.50E-04 357 R CRT3Y 
rs6697228 (NC) 1 C8A 0.142 -11.599 11.018 6.93E-04 187 D CRT1_5Y 
Table 4 
 
A 
 
SNP (effect) Chr Gene MAF Coefficient SE OR p-value N effect 
rs696764 (NC) 5 C9 0.135 1.671 0.557 5.317 1.72E-04 323 I 
rs3886100 (NC) 1 CR1 0.421 1.064 0.299 2.898 2.88E-04 362 R 
rs11672613 (NC) 19 C3 0.432 0.549 0.164 1.732 6.07E-04 370 D 
rs831627 (NC) 11 CD59 0.035 1.555 0.566 4.735 1.67E-03 359 R 
rs6661764 (NC) 1 CR1 0.268 0.579 0.198 1.784 2.72E-03 362 R 
rs13157656 (MIS) 5 C7 0.221 1.047 0.376 2.849 3.37E-03 311 I 
rs696760 (NC) 5 C9 0.102 1.966 0.713 7.142 3.95E-03 323 I 
rs3795341 (NC) 1 CFHR4 0.169 -0.528 0.196 0.590 6.42E-03 363 R 
rs1048118 (S) 23 CFP 0.243 -0.391 0.144 0.676 6.47E-03 359 R 
rs17020983 (NC) 1 C4BPA 0.064 -1.811 0.679 0.163 6.88E-03 321 I 
 
 
B 
 
SNP (effect) Chr Gene MAF Coefficient SE OR p-value N effect 
rs7732104 (NC) 5 C7 0.166 -0.705 0.210 0.494 8.17E-04 536 R 
rs7040603 (NC) 9 C5 0.194 -1.137 0.372 0.321 1.56E-03 506 I 
rs3181274 (NC) 11 CD59 0.351 -0.514 0.165 0.598 1.70E-03 539 D 
rs1444903 (NC) 5 C6 0.123 -0.741 0.240 0.477 1.80E-03 433 R 
rs17514136 (NC) 9 Ficolin2 0.270 -0.534 0.175 0.586 2.16E-03 538 R 
rs7951 (S) 19 C3 0.074 2.624 0.872 13.791 2.36E-03 523 I 
rs4926 (MIS) 11 Serp1 0.261 0.798 0.278 2.221 3.50E-03 529 I 
rs3886100 (NC) 1 CR1 0.421 0.816 0.28 2.261 3.87E-03 538 D 
rs12722588 (NC) 10 IL2RA 0.174 -0.599 0.209 0.549 4.27E-03 539 D 
rs11569450 (NC) 19 C3 0.105 0.841 0.314 2.319 4.48E-03 539 D 
 
Figure legend 
 
Figure 1. Kaplan-Meier plots of graft survival stratified by donor rs4935047 genotype.  Top 
line (solid, straight ticks) is for the major homozygote; middle line (dotted, cross ticks) is for 
the heterozygote; bottom line (dashed, star ticks) is for the minor homozygote.  
 
Figure 2. Box plots of KCL 1- vs 3-year serum creatinine stratified by recipient rs930507 
genotype.  Numbers in each group are also indicated. 
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